Publicação
Five-Year Sustained Response to Nivolumab in Hepatocellular Carcinoma following Serious Immune-Related Hepatitis.
| Resumo: | Introduction: Hepatocellular carcinoma (HCC) holds high cancer mortality worldwide. Immunotherapy-based combination therapy, currently the first-line (1L) standard of care in advanced HCC, has shifted the treatment paradigm concerning both efficacy and safety outcomes. Data on immune-related adverse event surrogacy for efficacy outcomes are mixed. Case report: We report the case of a 58-year-old male with chronic hepatitis C virus infection who presented with a voluminous shoulder HCC metastasis. Albeit an initial significant biochemical response with 1L sorafenib, progressive disease after 3 months plus a bleeding complication led to treatment discontinuation. Second-line nivolumab, although yielding a rapid clinical and biochemical response, was permanently ceased after 12 weeks due to a grade 3 immune-related hepatitis. Notably, 5 years post-treatment, the patient sustains a major biochemical and radiographic response. Discussion: This case highlights an unusual and sustained response to nivolumab treatment in HCC, following early treatment discontinuation due to severe hepatotoxicity. |
|---|---|
| Autores principais: | Mendes, José Leão |
| Outros Autores: | Spencer, Ana Sofia; Pimentel, João Cabral; Sardinha, Mariana; Ferreira, João Boavida; da Luz, Ricardo |
| Assunto: | Drug-related side effects and adverse reactions Hepatocellular carcinoma Immune checkpoint inhibitors Nivolumab Progression-free survival HSJ PAT CLIN HSAC ONC |
| Ano: | 2025 |
| País: | Portugal |
| Tipo de documento: | texto |
| Tipo de acesso: | acesso aberto |
| Instituição associada: | Centro Hospitalar de Lisboa Central, EPE (CHLC) |
| Idioma: | inglês |
| Origem: | Repositório do Centro Hospitalar de Lisboa Central, EPE |
| Resumo: | Introduction: Hepatocellular carcinoma (HCC) holds high cancer mortality worldwide. Immunotherapy-based combination therapy, currently the first-line (1L) standard of care in advanced HCC, has shifted the treatment paradigm concerning both efficacy and safety outcomes. Data on immune-related adverse event surrogacy for efficacy outcomes are mixed. Case report: We report the case of a 58-year-old male with chronic hepatitis C virus infection who presented with a voluminous shoulder HCC metastasis. Albeit an initial significant biochemical response with 1L sorafenib, progressive disease after 3 months plus a bleeding complication led to treatment discontinuation. Second-line nivolumab, although yielding a rapid clinical and biochemical response, was permanently ceased after 12 weeks due to a grade 3 immune-related hepatitis. Notably, 5 years post-treatment, the patient sustains a major biochemical and radiographic response. Discussion: This case highlights an unusual and sustained response to nivolumab treatment in HCC, following early treatment discontinuation due to severe hepatotoxicity. |
|---|
Atividades financiadas
Não foram encontrados projetos financiados.